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| INTRODUC TI ON
Hepatocellular carcinoma (HCC) is a primary cancer of the liver.
Although many management and therapeutic strategies have been established, recurrence of HCC is not uncommon. 1 Surgical resection, the main treatment for HCC, offers some hope for longterm cure, but for prevention of both metastasis and recurrence, a new chemotherapeutic strategy is needed. The process of recurrence begins long before signs or symptoms appear. Stress has been implicated in tumor growth and progression. [2] [3] [4] The sympathetic nervous system and hypothalamic-pituitary-adrenal axis regulate the release of stress-related hormones such as cortisol, catecholamines and neuropeptides. 5 These mediators can trigger tumor antigenicity and modulate the immune response to tumor cells. There is some evidence that glucocorticoids and sympathetic neurotransmitters directly affect tumor cell growth and survival. 2 Several neuropeptides are known to regulate liver function not only through the central nervous system but also through the autonomic nervous system. 6, 7 Vasoactive intestinal peptide (VIP) is one of these neuropeptides. VIP is a 28-amino acid neuroendocrine mediator. It has 68% identity at the amino acid level with pituitary adenylate cyclase-activating polypeptide (PACAP) and belongs to the secretin peptide family. 8 Although VIP has a wide range of biological activity, it is present mainly in the gastric mucosa and is involved, as a hormone, in the regulation of gastric function. VIP receptors are of 2 subtypes: vasoactive intestinal polypeptide receptors 1 and 2 (VPAC1 and VPAC2, respectively). VPAC1 is found in the liver, lung, kidney and prostate, 9 whereas VPAC2 is found mainly in smooth muscle and in vessels. 9 Studies have revealed expression of VIP receptors in several human carcinomas, including HCC, and in vitro studies have shown that VIP inhibits proliferation of hepatoma and glioma cells. [10] [11] [12] [13] [14] However, the mechanisms by which VIP modulates HCC pathogenesis remain unknown. In the study described herein, we confirmed expression of VIP in HCC tissues, and we showed the effects of VIP in the Huh7 HCC cell line in vitro.
| MATERIAL S AND ME THODS

| Reagents
Vasoactive intestinal peptide (VIP) antibodies is included in Table 1 .
| Human hepatocellular carcinoma and noncancer liver tissues
Samples of human hepatocellular carcinoma (HCC) tissue were obtained from 12 patients undergoing partial hepatectomy at St.
Marianna University Hospital. Written informed consent for use of the resected tissues for research purposes had been provided by each of the patients prior to the surgery. The tissue samples were stored in the internal human tissue bank and were managed using anonymized numbers. Some tissues were from patients with hepatitis B virus-related HCC (n = 3), some were from patients with hepatitis C virus-related HCC (n = 3), some were from patients with nonvirus-related HCC (n = 3), and some were from patients with liver metastases from colorectal cancer (n = 3). All of HCC specimens were primary liver cancer. Once obtained, the surgical specimens were immediately frozen in liquid nitrogen.
Samples of noncancer liver tissue that had been obtained from 
| Assay of Huh7 cell proliferation
| Western blot analysis
| Immunohistochemistry
Immunohistochemical staining for VIP, VPAC1 and VPAC2 was 
| Immunostaining
Huh7 (2 × 10 4 ) cells were cultured on a microchamber slide and allowed to adhere for 24 hours. The slide was fixed in cold acetone for 15 minutes and blocked with 2% skim milk for 30 minutes.
Immunoreactivity in sections was visualized with the use of an LSAB alkaline phosphatase kit (Dako) according to the manufacturer's instructions. Tissues were then counterstained with hematoxylin.
| Assay of apoptosis of human hepatocellular carcinoma cells
For TMB substrate was added, and optical density was measured at 450 nm.
| Assay of intracellular cAMP
| Statistical analysis
Data are shown as mean ± SEM. The Steel-Dwass test for multiple comparisons was used to evaluate differences between respective groups. All statistical analyses were performed with JMP 13 (SAS Institute, Cary, NC, USA), and P < .05 was considered significant. Furthermore, the expressions of VIP and VPAC were also observed in cancer cells. Fewer VPAC1-positive and VPAC2-positive cells were found in the noncancer liver and liver metastases ( Figure 1A ).
Strong staining for VIP and the 2 VIP receptors was observed in the nonvirus-related HCC tissues and adjacent nontumorous tissues;
staining for VIP and its receptors was also strong in the Huh7 cells ( Figure 1B) . 
and 95.5 ± .9%, respectively; P < .05) in comparison to cell proliferation in untreated cells (100.0 ± 1.0%; Fig. 2A ). Because Huh7 cells are derived from Japanese patients and differentiated human liver cancer functions, Huh7 cells were used for detailed mechanism of cell proliferation in the experiment. 15 Proliferation was increased in the untreated cells. Conversely, proliferation was slightly 
| Apoptosis of primary hepatocytes cultured with vasoactive intestinal peptide
Apoptosis was induced in the 2 types of primary HCC cells cultured with 10 −10 M VIP. Apoptosis was not induced in the untreated primary HCC cells ( Figure 2D ).
| cAMP concentrations and CREB and pCREB levels in Huh7 cells cultured with vasoactive intestinal peptide
The concentration of intracellular cAMP (.5 ± .1 nmol/L) was significantly decreased in Huh7 cells cultured with VIP ( Figure 3A) . In addition, expression of CREB was significantly decreased in the nuclei of Huh7 cells cultured with VIP 10 −11 M, VIP 10 −10 M and VIP 10 −9 M (48.3 ± 6.6%, 45.1 ± 4.9% and 53.7 ± 5.4%, respectively; Figure 3B ).
The pCREB levels in Huh7 cells cultured with VIP 10 −11 M and VIP 10 −9 M were significantly decreased ( Figure 3C ). We next examined whether the VIP-induced inhibition of the cAMP/CREB activity was mediated by the VIP receptors. When Huh7 cells were pretreated with VIP receptor antagonist, there was no reduction in the cAMP concentration ( Figure 3D ). were also unchanged in VIP-treated Huh7 cells ( Figure 4D ). 
| Effects of [D-p-
| D ISCUSS I ON
The liver is indispensable for the maintenance of life and has a wide range of functions including, for example, detoxification, glycogen storage, protein and fat synthesis, and protein metabolism. 16 It is have shown association between release of neural transmitters and both tumor development and tumor metastasis. [17] [18] [19] For example, substance P promotes tumor cell proliferation and angiogenesis. 20 Alternatively, somatostatin inhibits the tumor growth, and, thus, somatostatin analogue is used effectively for treatment of liver or pancreatic cancer. 21, 22 Overexpression of VIP receptors VPAC1
and VPAC2 is seen in many human cancers. 9,23,24 Although, these receptors are known to be expressed in HCC, their roles in tumor growth and progression remain undetermined. Thus, we investigated the expression of both VIP and its receptors in noncancer liver and in HCC and their influence on the pathogenesis of HCC.
Although VIP and its receptors were not prominent in noncancer liver tissue, they were clearly present in all HCC tissues, whether or not the HCC was derived from hepatitis. VIP, VPAC1 and VPAC2
were localized to both tumorous and nontumorous regions. That is, expression of VIP and its receptors might not be related to hepatitis virus infection.
These findings indicate that VIP is produced in hepatocytes and in tumor cells and that VIP can influence HCC cells through its receptors. CREB and Bcl-xL proteins play important roles in the resistance of cancer cells to apoptosis induction and, thus, contribute to tumor growth and metastasis. Expression of dominant-negative CREB has been shown to decrease the carcinogenic and metastatic potential of cancer cells. 31 Decreased CREB phosphorylation and subsequent downregulation of Bcl-xL under PKCκ suppression contribute to the hepatic apoptosis during sepsis. 32 These results suggest that VIP-induced apoptosis is mediated via a mitochondrial death pathway and is caused by downregulation of the cAMP/CREB pathway.
We speculated that pretreatment with cAMP/PKA inhibitor The reason for the discrepant result was that Rp-cAMP had the same effect as a partial agonist for cAMP activation. Gerdin et al
showed that a PKA-independent signaling mechanism is mediated by another cAMP-binding protein and a subsequent signaling pathway, and such a protein was later identified as an exchange protein directly activated by cAMP (Epac). 33 ,34 PACAP, which shows high sequence homology to VIP, leads to neuronal differentiation and CREB activation via the Epac signaling pathway. 35, 36 Epac signaling (ie, PKA-independent signaling) may contribute to VIP-induced increase in apoptosis of HCC cells. Further studies are needed to clarify the mechanism.
In conclusion, we showed that VIP and VIP receptors are expressed in HCC cells and that they act to decrease cell proliferation and increase apoptosis. Cytokines, antiviral agents and anticancer agents are often used in combination to treat HCC. VIP should be noted as a neuropeptide capable of inducing apoptosis of malignant tumor cells. The action of VIP alone is weak, having decreased HCC cell proliferation by only 20%, but the combined use of VIP or VIP analogue and anticancer drugs is suggested and has, in fact, been proposed previously. 37 Our findings point to new pharmacological strategies that can be used to inhibit cancer progression.
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